266 related articles for article (PubMed ID: 25971659)
1. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.
Hassanein M; Hight MR; Buck JR; Tantawy MN; Nickels ML; Hoeksema MD; Harris BK; Boyd K; Massion PP; Manning HC
Mol Imaging Biol; 2016 Feb; 18(1):18-23. PubMed ID: 25971659
[TBL] [Abstract][Full Text] [Related]
2. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF
Schulte ML; Hight MR; Ayers GD; Liu Q; Shyr Y; Washington MK; Manning HC
Mol Imaging Biol; 2017 Jun; 19(3):421-428. PubMed ID: 27770401
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
4. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[
Pollard AC; Paolillo V; Radaram B; Qureshy S; Li L; Maity T; Wang L; Uddin MN; Wood CG; Karam JA; Pagel MD; Piwnica-Worms D; Millward SW; Fowlkes NW; Norton W; Engel BJ; Pisaneschi F; Zacharias NM
Mol Imaging Biol; 2022 Dec; 24(6):959-972. PubMed ID: 35732988
[TBL] [Abstract][Full Text] [Related]
5. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
6. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
7. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents.
Ploessl K; Wang L; Lieberman BP; Qu W; Kung HF
J Nucl Med; 2012 Oct; 53(10):1616-24. PubMed ID: 22935578
[TBL] [Abstract][Full Text] [Related]
9. Alanine and glycine conjugates of (2S,4R)-4-[
Zha Z; Ploessl K; Lieberman BP; Wang L; Kung HF
Nucl Med Biol; 2018 May; 60():19-28. PubMed ID: 29525446
[TBL] [Abstract][Full Text] [Related]
10. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
11. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.
Lieberman BP; Ploessl K; Wang L; Qu W; Zha Z; Wise DR; Chodosh LA; Belka G; Thompson CB; Kung HF
J Nucl Med; 2011 Dec; 52(12):1947-55. PubMed ID: 22095958
[TBL] [Abstract][Full Text] [Related]
13. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
14. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.
Hassanein M; Qian J; Hoeksema MD; Wang J; Jacobovitz M; Ji X; Harris FT; Harris BK; Boyd KL; Chen H; Eisenberg R; Massion PP
Int J Cancer; 2015 Oct; 137(7):1587-97. PubMed ID: 25821004
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
16. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
17. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
18. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.
Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M
Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755
[TBL] [Abstract][Full Text] [Related]
19. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
[TBL] [Abstract][Full Text] [Related]
20.
Liu H; Han Y; Li J; Qin M; Fu Q; Wang C; Liu Z
Mol Pharm; 2018 Mar; 15(3):947-954. PubMed ID: 29308900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]